The promise of novel molecular markers in bladder cancer

International Journal of Molecular Sciences

Volumn 15, Issue 12, 2014, Pages 23897-23908

  Miremami, Jahan ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Bladder cancer; MiRNA; Tumor markers; Urinary markers; Urothelial carcinoma

Indexed keywords

BIOLOGICAL MARKER; CADHERIN; EPITHELIAL CELL ADHESION MOLECULE; HYALURONIDASE; MATRIX METALLOPROTEINASE; MICRORNA; MICRORNA 130B; MICRORNA 140; MICRORNA 141; MICRORNA 142; MICRORNA 187; MICRORNA 18A; MICRORNA 199; MICRORNA 204; MICRORNA 205; MICRORNA 25; MICRORNA 29C; MICRORNA 3P; MOLECULAR MARKER; NICOTINAMIDE METHYLTRANSFERASE; NUCLEAR MATRIX PROTEIN; SURVIVIN; TUMOR ANTIGEN; UNCLASSIFIED DRUG; TRANSCRIPTOME; TUMOR MARKER;

BLADDER CANCER; CANCER PROGNOSIS; CIRCULATING TUMOR CELL; COST EFFECTIVENESS ANALYSIS; CYSTOSCOPY; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE CONTROL; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; URINE CYTOLOGY; WESTERN BLOTTING; ZYMOGRAPHY; GENETICS; METABOLISM; PROGNOSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; TUMOR EMBOLISM; URINARY BLADDER NEOPLASMS;

BIOMARKERS, TUMOR; HUMANS; MICRORNAS; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRANSCRIPTOME; URINARY BLADDER NEOPLASMS;

EID: 84919782054     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151223897     Document Type: Review

References (30)

1. Murphy, C.; Karnes, J. Bladder cancer in males: A comprehensive review of urothelial carcinoma of the bladder. J. Mens Health 2014, 6, 18-27.
2. Smith, Z.L.; Guzzo, T.J. Urinary markers for bladder cancer. F1000Prime Rep. 2013, 5, 5-21.
3. Botterman, M.F.; Pashos, C.L.; Redaelli, A.; Laskin, B.; Hauser, R. The health economics of bladder cancer: A comprehensive review of published literature. Pharmacoeconomics 2003, 21, 1315-1330.
4. Hong, Y.M.; Loughlin, K.R. Economic impact of tumor markers in bladder cancer surveillance. Urology 2008, 71, 131-135.
5. Sievert, K.D.; Amend, B.; Nagele, U.; Schilling, D.; Bedke, J.; Horstmann, M.; Hennenlotter, J.; Kruck, S.; Stenzl, A. Economic aspects of bladder cancer: What are the benefits and costs? World J. Urol. 2009, 27, 295-300.
6. Grossman, H.B.; Soloway, M.; Messing, E.; Katz, G.; Stein, B.; Kassbian, V.; Shen, Y. Surveillance for recurrent bladder cancer using point-of-care proteomic assay. JAMA 2006, 295, 299-305.
7. Lokeshwar, V.B.; Habuchi, T.; Grossman, H.B.; Murphy, W.M.; Hautmann, S.H.; Hemstreet, G.P., III; Bonog, A.V.; Getzenbergh, R.H.; Goebelli, P.; Schmitz-Dräger, B.J., et al. Bladder tumor markers beyond cytology: International Consensus panel on bladder tumor markers. Urology 2005, 66, 35-63.
8. Hajdinjak, T. UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing. Urol. Oncol. 2008, 26, 646-651.
9. Huber, S.; Schwentner, C.; Taeger, D.; Pesch, B.; Nasterlack, M.; Leng, G; Mayer, T.; Gawrych, K.; Bonberg, N.; Pelster, M., et al. Nuclear matrix protein-22: Prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study. BJU Int. 2012, 110, 699-708.
10. Ku, J.H.; Godoy, G.; Amiel, G.E.; Lerner, S.P. Urine surviving as a diagnostic biomarker for bladder cancer: A systematic review. BJUI 2012, 110, 630-636.
11. Agarwal, P.K.; Black, P.C.; Kamat, A.M. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J. Urol. 2008, 26, 39-44.
12. Behrens, T.; Bonberg, N.; Casjens, S.; Pesch, B.; Bruning, T. A practical guide to the epidemiological practice and standards in the identification and validation of diagnostic markers using a bladder cancer example. Biochim. Biophys. Acta 2014, 1844, 145-155.
13. Todenhoffer, T.; Hennenlotter, J.; Esser, M.; Morhardt, S.; Tews, V.; Aufderklamm, S.; Gakis, G.; Kuehs, U.; Stenzl, A.; Schwentner, C. Combined application of cytology and molecular urine markers to improve the detection of urothelial carcinoma. Cancer Cytopathol. 2013, 121, 252-260.
14. Eissa, S.; Badr, S.; Barakat, M.; Zaghloul, A.S.; Mohanad, M. The diagnostic efficacy of urinary survivin and hyaluronidase mRNA as urine markers in patients with bladder cancer. Clin. Lab. 2013, 59, 893-900.
15. Eissa, S.; Badr, S.; Elhamid, S.A.; Helmy, A.S.; Nour, M.; Esmat, M. The value of combined use of survivin mRNA and matrix metalloproteinase 2 and 9 for bladder cancer detection in voided urine. Dis. Markers 2013, 34, 57-62.
16. Kamat, A.M.; Karam, J.A.; Grossman, H.B.; Kader, A.K.; Munsell, M.; Dinney, C.P. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. BJU Int. 2011, 118, 1119-1124.
17. Sartini, D.; Muzzonigro, G.; Milanese, G.; Pozzi, V.; Vici, A.; Morgant, S.; Rossi, V.; Mazzucchelli, R.; Montironi, R.; Emanuelli, M. Up-regulation of tissue and urinary nicotinamide N-methyltransferase in bladder cancer: Potential for the development of a urine-based diagnostic test. Cell Biochem. Biophys. 2013, 65, 473-483.
18. Wang, P.; Lin, S.L.; Zhang, L.H.; Li, Z.; Liu, Q.; Gao, J.X.; Liu, D.M.; Bo, J.J.; Huang, Y.R. The prognostic value of P-cadherin in non-muscle-invasive bladder cancer. Eur. J. Surg. Oncol. 2014, 40, 255-259.
19. Bryan, R.T.; Shimwell, N.J.; Wei, W.; Devall, A.J.; Pirrie, S.J.; James, N.D.; Zeegers, M.P.; Cheng, K.K.; Martin, A.; Ward, D.G. Urinary EpCAM in urothelial bladder cancer patients: Characterization and evaluation of biomarker potential. Br. J. Cancer 2014, 110, 679-685.
20. Ratert, N.; Meyer, H.A.; Jung, M.; Lioudmer, P.; Mollenkopf, H.J.; Wagner, I.; Miller, K.; Kilic, E.; Erbersdobler, A.; Weikert, S, et al. miRNA profiling identifies candidate miRNAs for bladder cancer diagnosis and clinical outcome. J. Mol. Diagn. 2013, 15, 695-705.
21. Rosenberg, E.; Baniel, J.; Spector, Y.; Faerman, A.; Meiri, A.; Aharonov, R.; Margel, D.; Goren, Y.; Nativ, O. Predicting progression of bladder urothelial carcinoma using microRNA expression. BJU Int. 2013, 112, 1027-1034.
22. Mengual, L.; Lozano, J.J.; Ingelmo-Torres, M.; Gazquez, C.; Ribal, M.J.; Alcaraz, A. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int. J. Cancer 2013, 133, 2631-2641.
23. Van Rhijn, B.W; Zuiverloon, T.C.; Vis, A.N.; Radvanyi, F.; van Leenders, G.J.; Ooms, B.C.; Kirkelsa, W.J.; Lockwoodg, G.A.; Boevéb, E.R.; Jöbsish, A.C., et al. Molecular grade (FGFR3?MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur. Urol. 2010, 58, 433-441.
24. Dorn, G.W., II; Matkovich, S.J. Menage a trois: Intimate relationship between microRNA, long noncoding RNA, and mRNA. Circ. Res. 2014, 144, 1362-1365.
25. Descotes, F.; Dessen, P.; Bringuier, P.P.; Decaussin, M.; Martin, P.M.; Adams, M.; Villers, A.; Lechevallier, E.; Rebillard, X.; Rodriguez-Lafrasse, C., et al. Microrray gene expression profiling and analysis of bladder cancer supports the sub-classification of T1 tumours into T1a and T1b stages. BJU Int. 2014, 113, 333-342.
26. Liberko, M.; Kolostova, K.; Bobek, V. Essentials of circulating tumor cells for clinical research and practice. Crit. Rev. Oncol. Hematol. 2013, 88, 338-356.
27. Hong, B.; Zu, Y. Detecting circulating tumor cells: Current challenges and new trends. Theranostics 2013, 3, 377-394.
28. Gazzaniga, P.; Gradilone, A.; Berardinis, E.D.; Busetto, G.M.; Raimondi, C.; Gandini, O.; Nicolazzo, C.; Petracca, A.; Vincenzi, B.; Farcomeni, A., et al. Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: A CellSearch analysis. Ann. Oncol. 2012, 23, 2352-2356.
29. Flaig, T.W.; Wilson, S.; Bokhoven, A.; Varella-Garcia, M.; Wolfe, P.; Maroni, P.; Genovac, E.E.; Moralese, D.; Scott Luciac, M. Detection of circulating tumor cells in metastatic and clinically localized urothelial carcinoma. Urology 2011, 78, 863-867.
30. Kamat, A.M.; Hegarty, P.K.; Gee, J.R.; Clark, P.E.; Svatek, R.S.; Hegarty, N.; Shariat, S.F.; Xylinas, E.; Schmitz-Dräger, B.J.; Lotan, Y., et al. ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. Eur. Urol. 2013, 63, 4-15.